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Abstract Colchicine is the treatment of choice in familial
Mediterranean fever (FMF) for the prevention of both attacks
and secondary amyloidosis. The overall nonresponder rate is
about 5–10%. Anakinra is known to have good effectiveness
in a severe autoinflammatory syndrome [chronic infantile
neurologicalcutaneous and articular (CINCA) syndrome] and
other recurrent hereditary periodic fevers. Pyrin—the protein
involved in FMF—has a role in activating the proinflamma-
tory cytokine interleukin (IL)-1β. We report the effectiveness
of the addition of an IL-1-receptor inhibitor (anakinra) to
colchicine in controlling the febrile attacks and acute phase
response in an adolescent with FMF resistant to colchicine.
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Case report
A 15-year-old girl with familial Mediterranean fever (FMF)
was admitted to our hospital because of the persistence of
recurrent fever attacks (twice a month), accompanied by chest
and abdominal pain with headache, despite taking colchicine
at a high dose (2 mg/kg per day). She suffered severe
discomfort and complained of several school absences.
Acute phase reactants [erythrocyte sedimentation rate
(ESR) 110, C-reactive protein (CRP) 43 mg%] and serum
interferon-γ (125.4 pg/ml) were high during the crises.
There was no proteinuria, but given the severity of the
clinical picture, we performed a rectal biopsy to definitely
exclude the presence of amyloidosis and it was negative.
Anakinra was started at 50 mg/day (1 mg/kg per day)
subcutaneously, without stopping colchicine. Approval was
obtained from an Ethics Committee (Burlo Garofolo Health
Authority).
In the following 3 months the patient developed only
three mild episodes of abdominal pain without fever, which
resolved in a few hours. During these episodes acute phase
reactants were negative. Moreover, serum interferon-γ was
low (23 pg/ml).
After 3 months, anakinra was discontinued to confirm its
real efficacy, without stopping colchicine. Following this
interruption, the girl complained of eight fever attacks in
3 months accompanied by abdominal pain, vomiting, chest
pain, and headache. Anakinra was reintroduced. Since then
(15 months offollow-up), the patient has been in good health,
without any fever attacks or abdominal or chest pain.
There have been no adverse effects due to anakinra,
apart from minor local stinging and erythema at the
injection sites, which gradually diminished.
Discussion
Colchicine is the recommended treatment of FMF since it can
preventthefebrileattacksandthedevelopmentofamyloidosis,
even though a few patients develop amyloidosis also when on
colchicine treatment [3, 5]. However, approximately one third
of the patients have a partial remission and about 5–10% are
nonresponders [3]; another 2–5% do not tolerate the drug
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Trieste, Italywell [3]. In single case reports several drugs (interferon-α,
infliximab, thalidomide, etanercept) have been suggested as a
possible alternative treatment for these cases [3, 6].
Anakinra is a recombinant form of the human interleukin
(IL)-1-receptor antagonist that targets type I IL-1-receptor
which is expressed in many tissues. There are some studies
and case reports that show a good efficacy of anakinra in a
severe autoinflammatory syndrome (CINCA, chronic infantile
neurological cutaneous and articular syndrome) [2] and other
recurrent hereditary periodic fevers [4]. Despite the elevated
costs (approximately 50 € per 100 mg) its use appears justified
in some inflammatory diseases that lack alternative treatments.
Since pyrin—the protein involved in FMF—activates the
precursor form of IL-1β into its biologically active fragments
there is a rationale for testing anakinra in FMF [1, 5].
Moreover, anakinra did appear to be effective in suppressing
acute phase reactants in a patient with FMF (a nonresponder
to the treatment with colchicine) and amyloidosis [1].
In our case, the addition of anakinra to colchicine had a
dramatic therapeutic benefit without relevant side effects.
As the febrile attacks recurred after discontinuing anakinra
and disappeared again after reintroduction, we believe in
the real therapeutic efficacy of this drug. In light of the
present evidence [3, 5], colchicine should be continued in
order to prevent further developments of amyloidosis.
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